Idiopathic interstitial pneumonia natural history, complications and prognosis: Difference between revisions
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
Line 9: | Line 9: | ||
==Major Idiopathic Interstitial Pneumonias== | ==Major Idiopathic Interstitial Pneumonias== | ||
* | * '''Chronic fibrosing IIPs''': | ||
:* [[Idiopathic pulmonary fibrosis]] | :* '''[[Idiopathic pulmonary fibrosis]]''' | ||
:* | ::* The most common and the worst prognosis of chronic IIPs. | ||
* [[Acute/Subacute IIPs | :* '''[[Idiopathic nonspecific interstitial pneumonia]]''' | ||
::* Better outcome than IPF. | |||
::* Cellular type is more common than Fibrotic type. | |||
::* The cellular NSIP is better than fibrosing type of NSIP. | |||
::* Larger studies are needed to understand the clinical course of NSIP, however smaller studies showed that the 10-Yr survival of fibrotic NSIP is 35%,<ref name="Travis-2000">{{Cite journal | last1 = Travis | first1 = WD. | last2 = Matsui | first2 = K. | last3 = Moss | first3 = J. | last4 = Ferrans | first4 = VJ. | title = Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. | journal = Am J Surg Pathol | volume = 24 | issue = 1 | pages = 19-33 | month = Jan | year = 2000 | doi = | PMID = 10632484 }}</ref> 5-Yr survival rate is 43%, <ref name="Nicholson-2000">{{Cite journal | last1 = Nicholson | first1 = AG. | last2 = Colby | first2 = TV. | last3 = du Bois | first3 = RM. | last4 = Hansell | first4 = DM. | last5 = Wells | first5 = AU. | title = The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. | journal = Am J Respir Crit Care Med | volume = 162 | issue = 6 | pages = 2213-7 | month = Dec | year = 2000 | doi = 10.1164/ajrccm.162.6.2003049 | PMID = 11112140 }}</ref> 25% deterioration of lung function despite treatment.<ref>{{Cite journal | last1 = Kondoh | first1 = Y. | last2 = Taniguchi | first2 = H. | last3 = Yokoi | first3 = T. | last4 = Nishiyama | first4 = O. | last5 = Ohishi | first5 = T. | last6 = Kato | first6 = T. | last7 = Suzuki | first7 = K. | last8 = Suzuki | first8 = R. | title = Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. | journal = Eur Respir J | volume = 25 | issue = 3 | pages = 528-33 | month = Mar | year = 2005 | doi = 10.1183/09031936.05.00071004 | PMID = 15738299 }}</ref> | |||
* '''Acute/Subacute IIPs''': | |||
:* [[Cryptogenic organizing pneumonia]] | :* [[Cryptogenic organizing pneumonia]] | ||
:* [[Acute interstitial pneumonia]] (Hamman-Rich Syndrome) | :* [[Acute interstitial pneumonia]] (Hamman-Rich Syndrome) | ||
* | * '''Smoking-related IIPs''': | ||
:* [[Respiratory bronchiolitis-interstitial lung disease]] | :* [[Respiratory bronchiolitis-interstitial lung disease]] | ||
Revision as of 17:24, 18 November 2013
Idiopathic Interstitial Pneumonia Microchapters |
Differentiating Idiopathic interstitial pneumonia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Idiopathic interstitial pneumonia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Idiopathic interstitial pneumonia natural history, complications and prognosis |
FDA onIdiopathic interstitial pneumonia natural history, complications and prognosis |
CDC on Idiopathic interstitial pneumonia natural history, complications and prognosis |
Idiopathic interstitial pneumonia natural history, complications and prognosisin the news |
on Idiopathic interstitial pneumonia natural history, complications and prognosis |
Directions to Hospitals Treating Idiopathic interstitial pneumonia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Natural history and Complications
Major Idiopathic Interstitial Pneumonias
- Chronic fibrosing IIPs:
-
- The most common and the worst prognosis of chronic IIPs.
-
- Better outcome than IPF.
- Cellular type is more common than Fibrotic type.
- The cellular NSIP is better than fibrosing type of NSIP.
- Larger studies are needed to understand the clinical course of NSIP, however smaller studies showed that the 10-Yr survival of fibrotic NSIP is 35%,[1] 5-Yr survival rate is 43%, [2] 25% deterioration of lung function despite treatment.[3]
- Acute/Subacute IIPs:
- Cryptogenic organizing pneumonia
- Acute interstitial pneumonia (Hamman-Rich Syndrome)
- Smoking-related IIPs:
Rare Idiopathic Interstitial Pneumonias
- Idiopathic lymphoid interstitial pneumonia
- Idiopathic pleuroparenchymal fibroelastosis
Biomarkers
The functional lung capacity, pulmonary functions and mortality have been linked to some biomarkers. For example some studies showed that rapidly deteriorating lung function and higher mortality have been associated with high serum level of epithelial or macrophage-related proteins such as SP-A, SP-D, KL-6 (Krebs von den Lungen-6), CCL18 (chemokine ligand-18), and MMP-7 (matrix metalloproteinase-7) [4] [5] [6]
References
- ↑ Travis, WD.; Matsui, K.; Moss, J.; Ferrans, VJ. (2000). "Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia". Am J Surg Pathol. 24 (1): 19–33. PMID 10632484. Unknown parameter
|month=
ignored (help) - ↑ Nicholson, AG.; Colby, TV.; du Bois, RM.; Hansell, DM.; Wells, AU. (2000). "The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis". Am J Respir Crit Care Med. 162 (6): 2213–7. doi:10.1164/ajrccm.162.6.2003049. PMID 11112140. Unknown parameter
|month=
ignored (help) - ↑ Kondoh, Y.; Taniguchi, H.; Yokoi, T.; Nishiyama, O.; Ohishi, T.; Kato, T.; Suzuki, K.; Suzuki, R. (2005). "Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia". Eur Respir J. 25 (3): 528–33. doi:10.1183/09031936.05.00071004. PMID 15738299. Unknown parameter
|month=
ignored (help) - ↑ Satoh, H.; Kurishima, K.; Ishikawa, H.; Ohtsuka, M. (2006). "Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases". J Intern Med. 260 (5): 429–34. doi:10.1111/j.1365-2796.2006.01704.x. PMID 17040248. Unknown parameter
|month=
ignored (help) - ↑ Prasse, A.; Probst, C.; Bargagli, E.; Zissel, G.; Toews, GB.; Flaherty, KR.; Olschewski, M.; Rottoli, P.; Müller-Quernheim, J. (2009). "Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis". Am J Respir Crit Care Med. 179 (8): 717–23. doi:10.1164/rccm.200808-1201OC. PMID 19179488. Unknown parameter
|month=
ignored (help) - ↑ Ishii, H.; Mukae, H.; Kadota, J.; Kaida, H.; Nagata, T.; Abe, K.; Matsukura, S.; Kohno, S. (2003). "High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia". Thorax. 58 (1): 52–7. PMID 12511721. Unknown parameter
|month=
ignored (help)